...
首页> 外文期刊>The American Journal of Cardiology >Meta-analysis of clinical studies comparing coronary artery bypass grafting with percutaneous coronary intervention and drug-eluting stents in patients with unprotected left main coronary artery narrowings.
【24h】

Meta-analysis of clinical studies comparing coronary artery bypass grafting with percutaneous coronary intervention and drug-eluting stents in patients with unprotected left main coronary artery narrowings.

机译:荟萃分析的临床研究比较了无保护的左主干狭窄患者的冠状动脉搭桥术与经皮冠状动脉介入治疗和药物洗脱支架的比较。

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this study was to compare the safety and efficacy of coronary artery bypass grafting (CABG) with percutaneous coronary intervention (PCI) using drug-eluting stents (DES) in patients with unprotected left main coronary artery (ULMCA) disease. The current American College of Cardiology and American Heart Association guidelines recommend CABG for the treatment of patients with ULMCA disease on the basis of clinical trials demonstrating a survival benefit with CABG compared to medical therapy. DES reduce the rate of target vessel revascularization compared with bare-metal stents in ULMCA PCI and may be a safe alternative to CABG. A meta-analysis was conducted of clinical studies comparing CABG and PCI with DES for ULMCA disease with respect to death; the composite of death, myocardial infarction, or stroke; and target vessel revascularization at 1 year follow-up. The analysis included 2,905 patients from 8 clinical studies (2 randomized trials and 6 nonrandomized studies). At 1-year follow-up, there was no significant difference between the CABG and DES groups in the risk for death (odds ratio [OR] 1.12, 95% confidence interval [CI] 0.80 to 1.56) or the composite end point of death, myocardial infarction, or stroke (OR 1.25, 95% CI 0.86 to 1.82). The risk for target vessel revascularization was significantly lower in the CABG group compared to the PCI group (OR 0.44, 95% CI 0.32 to 0.59). In conclusion, PCI with DES is safe and could represent a good alternative to CABG for selected cases in patients with ULMCA disease.
机译:这项研究的目的是比较在未保护的左主冠状动脉(ULMCA)疾病中使用药物洗脱支架(DES)的冠状动脉搭桥术(CABG)与经皮冠状动脉介入治疗(PCI)的安全性和有效性。当前的美国心脏病学会和美国心脏协会指南根据临床试验证明,CABG与药物治疗相比具有生存优势,因此建议CABG用于治疗ULMCA疾病的患者。与ULMCA PCI中的裸金属支架相比,DES降低了目标血管的血运重建率,可能是CABG的安全替代方法。对临床研究进行荟萃分析,比较CABG和PCI与DES在ULMCA疾病死亡方面的关系。死亡,心肌梗塞或中风的综合;并在1年的随访中进行目标血管血运重建。该分析包括来自8项临床研究(2项随机试验和6项非随机研究)的2905名患者。在1年的随访中,CABG和DES组之间的死亡风险(赔率[OR] 1.12,95%置信区间[CI] 0.80至1.56)或死亡的复合终点没有显着差异。 ,心肌梗塞或中风(OR 1.25,95%CI 0.86至1.82)。与PCI组相比,CABG组的目标血管血运重建风险显着降低(OR 0.44,95%CI 0.32至0.59)。总而言之,PCI与DES是安全的,对于某些患有ULMCA疾病的患者,可以替代CABG。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号